BUSINESS

• Eisai Gives Global R&D Updates on Dementia, Oncology
  July 1, 2016

• Filing for 1st Japan-Made Nucleic Acid Expected by Year-End If PIII Yields Positive Data
  July 1, 2016

• Toho Holdings Appoints Ex-Qol Exec Takada as Senior Executive Officer
  July 1, 2016

• Nichi-Iko Aims for 20% Share of Generic Market in “80% Generic Era”: President
  June 30, 2016

• Kyowa Kirin’s KRN23 Gets BT Designation for X-Linked Hypophosphatemia in Children
  June 30, 2016

• Novel Anti-HIV Agent Genvoya to Hit Japan Market on July 8: JT, Torii
  June 30, 2016

• Celgene Files Revlimid for ATL in Japan
  June 30, 2016

• Reconsider Appropriate Diabetes Drug Combos Including GLP-1 Agents: Diabetologist
  June 29, 2016

• MSD Initiates Long-Term Observational Study of Treatment with Oral Hypoglycemic Agents
  June 29, 2016

• Boehringer-Sanofi Asset Swap Slated to Close by Year’s End; Fate of Japan Units Subject to Future Discussions
  June 28, 2016

• Daiichi Sankyo, Servier Sign Sales Accord for Edoxaban in Canada
  June 28, 2016

• Takeda Returns Japan Rights for Some Amgen Products
  June 27, 2016

• Teijin Pharma Will Block Feburic Generic Erosions by Expanding Indications: President
  June 24, 2016

• Cellular Dynamics, US National Eye Institute Ink Pact to Advance Cell Transplantation Therapy for AMD
  June 24, 2016

• Univ. of Tokyo, Astellas to Codevelop Rice-Based Oral Cholera Vaccine
  June 24, 2016

• Sanofi’s Antibody Drug for Atopic Dermatitis Close to Regulatory Filing
  June 23, 2016

• Asahi Kasei Inks Collaboration with Finland’s Orion on Pain Therapies
  June 23, 2016

• Interview: Bayer Yakuhin Chief Spearheading Initiatives to Trigger Behavior Change in Employees
  June 23, 2016

• Fujifilm Inks 1st License Deal for Avigan Patents with Chinese Pharma
  June 23, 2016

• Takeda to Partner with US NPO for Joint Program to Explore Lead Compounds for TB Therapies
  June 23, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 466
• 467
• 468
• 469
• 470
• 471
• 472
• 473
• 474
• …
• Next ›
• 最終 »